Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues

Executive Summary

President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.


Related Content

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access
CVS CEO Larry Merlo On What Comes Next After Aetna Merger
No, It's Not Just Out-Of-Pocket Costs That Are A Problem, John Arnold Tells Pharma
The Inevitable Is Coming: Price Increases, Starting With Pfizer
US Drug Pricing: CMS Seeks Feedback On DTC Ad Enforcement Mechanism, Disclosure Statement
US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating
HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether
PBMs Play Outsized Role … In Hearing On Health Sector Consolidation
Medicare Value-Pricing Options Vary Widely In Part B Payment Experiment
CMS Payment Experiment Strains Legal Powers, Reimbursement Norms





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts